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ABSTRACT 
Background: The aim of the ACE-Obesity study was to determine the economic credentials of 
interventions which aim to prevent unhealthy weight gain in children and adolescents. We have 
reported elsewhere on the modelled effectiveness of 13 obesity prevention interventions in children. In 
this paper, we report on the cost results and associated methods together with the innovative 
approach to priority setting that underpins the ACE-Obesity study.  
Methods: The Assessing Cost Effectiveness (ACE) approach combines technical rigour with ‘due 
process’ to facilitate evidence-based policy analysis. Technical rigour was achieved through use of 
standardised evaluation methods, a research team that assembles best available evidence and 
extensive uncertainty analysis. Cost estimates were based on pathway analysis, with resource usage 
estimated for the interventions and their ‘current practice’ comparator, as well as associated cost 
offsets. Due process was achieved through involvement of stakeholders, consensus decisions informed 
by briefing papers and 2nd stage filter analysis that captures broader factors that influence policy 
judgements in addition to cost-effectiveness results. The 2nd stage filters agreed by stakeholders were 
‘equity’, ‘strength of the evidence’, ‘feasibility of implementation’, ‘acceptability to stakeholders’, 
‘sustainability’ and ‘potential for side-effects’. 
Results: The intervention costs varied considerably, both in absolute terms (from cost saving [6 
interventions] to in excess of AUD50m per annum) and when expressed as a ‘cost per child’ estimate 
(from <AUD1.0 [reduction of TV advertising of high fat foods/high sugar drinks] to AUD31,553 
[laparoscopic adjustable gastric banding for morbidly obese adolescents]). High costs per child 
reflected cost structure, target population and/or under-utilisation.  
Conclusions: The use of consistent methods enables valid comparison of potential intervention costs 
and cost-offsets for each of the interventions. ACE-Obesity informs policy-makers about cost-
effectiveness, health impact, affordability and 2nd stage filters for important options for preventing 
unhealthy weight gain in children. In related articles cost-effectiveness results and second stage filter 
considerations for each intervention assessed will be presented and analysed.   
BACKGROUND 
Obesity is now universally acknowledged as a major public health problem, both in children and adults 
[1-2]. This raises vital public health questions concerning what interventions are necessary to control 
the obesity epidemic; whether our early endeavours to confront obesity are the right choices; and 
whether they are sufficient to reverse the obesity trends. 

Scarcity of funds dedicated to public health also means that difficult choices of what to fund to reverse 
the trend in unhealthy weight gain are inevitable. While there is nothing new about the task of making 
difficult choices in health care, policy-makers are now discussing with renewed interest the issue of 
how to set priorities which are evidence-based. Often choices have been driven by historical, political 
or commercial imperatives, but the importance of ‘evidence-based policy’ is increasingly being 
recognised [3]. Cost-effectiveness analyses can provide additional evidence-based information to help 
decision-makers set priorities and answer difficult questions such as those posed above. But for cost-
effectiveness analysis to be taken seriously, economic analysts also need to address the broader 
concerns of decision-makers that go beyond simple formulae-based decision-making. 
In recognition of the need for ‘evidence-based’ information to guide policy on obesity prevention, the 
Department of Human Services in Victoria, Australia, commissioned the Assessing Cost-Effectiveness in 
Obesity (ACE–Obesity) project in 2004. The aim of the project was to assist state and national policy-
makers by providing best available modelled evidence on the effectiveness and cost-effectiveness of 
selected obesity prevention interventions, particularly amongst children and adolescents. ACE-Obesity 
followed earlier ACE studies in cancer [4], heart disease [5], and mental health [6-7], where the ACE 
approach was developed and successfully implemented. 
 
The purpose of this paper is to overview the ACE approach to priority setting, together with the specific 
methods used in the ACE-Obesity study. In a companion paper [8], detail was provided on the 
methods used to calculate the likely impact of 13 obesity interventions on BMI, measured through 
changes in ‘energy balance’ and then conversion to anticipated health gain (using Disability Adjusted 
Life Years averted – DALYs). In this paper we complement that overview of health benefit results and 
methods, by providing an overview of cost results and key methodological issues associated with 
costing for the same 13 interventions. The bringing together of the benefits and costs is dealt with in a 
separate paper on the cost-effectiveness results (Moodie et al, 2009, as yet unpublished).   
 THE ACE APPROACH TO PRIORITY SETTING 

While the importance and need for priority setting in health care is generally accepted, the central 
question of how priority setting is to be achieved remains contested. There are a variety of approaches 
and models available, offered from a range of disciplines [9]. There are models developed by 
behavioural scientists based on achieving consensus; by epidemiologists/clinicians based on needs 
assessment; by philosophers based on notions of social justice; and by economists based on achieving 
efficiency.  
 
A central issue is the extent to which priority setting approaches focus on ‘technical analysis’ or ‘due 
process’ for their legitimacy [9]. The ‘technical school’ is characterised by a reliance on rational 
decision rules, data sets and quantitative analysis. This school has in large part been the preserve of 
health economists (pursuing the goal of efficiency) and epidemiologists/clinicians (pursuing evidence-
based guidelines and/or needs-based equity). Decisions are based on quantitative analysis and/or 
application of the correct rules, whether efficiency and/or equity focused. Provided one accepts these 
principles, results should give guidance to decision-makers on how services should be ranked. 
 
In contrast, advocates of the ‘due process’ school question the assumption that it is possible to devise 
‘rational’ decision rules and see the technical approaches as based on a simplistic view of the health 
care system. Here the task is less to refine the technical basis of decision-making, than to construct a 
process that enables proper debate and discussion to occur. This does not mean implicit rationing, but 
instead a system whereby decisions are made explicitly and the reasoning behind specific judgements 
is clearly explained.  
 
The debate between the two schools, however, may be drawn too starkly in the literature [9-11]. 
There is no inherent conflict between action to provide more and better information on the costs, 
outcomes and evidence base for different interventions, and work to strengthen the processes for 
debating that information and arriving at judgements on priorities. The reality is that neither option 
alone is likely to fulfil the theoretical and practical requirements of an ideal approach to explicit priority 
setting. Both elements need to be involved in any approach to priority setting that is seeking strong 
theoretical foundations and empirical validity. The ‘ACE’ approach reflects our endeavours to develop 
such a joint approach.  
 
On the technical side, the ACE methodology applies the key economic concepts of ‘opportunity cost’; 
‘marginal analysis’ and a ‘clear concept of benefit’ using standardised evaluation methods clearly 
documented in an evaluation protocol [9,12,13]. Undertaking the evaluations in this way as part of the 
priority setting exercise, addresses the reservations expressed by many economists about the 
simplistic use of league tables, where economic studies are assembled from the literature with little 
regard to differences in methods, context and setting [13]. The key characteristics of the ACE approach 
are:   
 
• the rationale for the selection of interventions is clearly explained; 
• the evaluation methods are standardised, documented and open to scrutiny; 
• the setting, context and comparator is common to all interventions; 
• country specific data are used, wherever possible, for demography, health system costs and 
disease incidence/prevalence patterns;  
• information is assembled by a multi-disciplinary research team, preparing briefing papers to a 
standardised format agreed by a Working Group of stakeholders; 
• a range of results is reported (around point estimates) reflecting explicitly the uncertainty of 
cost, process, outcome and value estimates; and 
• the incremental cost effectiveness ratios are placed within a broader decision-making 
framework called ‘2nd stage filter’ analysis.  
 
ACE Working Groups generally consist of stakeholders recruited from topic experts, clinicians and 
practitioners, relevant community organisations and policy-makers.  The ACE approach aims to give 
these stakeholders a greater involvement in both the study design and conclusions, as recommended 
by the Panel on Cost Effectiveness in Health and Medicine [13]. The Working Group in ACE studies has 
an important role in achieving balance between the technical analyses and due process. On the 
technical side members contribute in areas of their expertise and discuss issues of method and 
evidence. On the ‘due process’ side, members ensure stakeholder interests and views are articulated; 
facilitate sensible interpretation of the technical analysis; assist with ‘value’ judgement aspects of the 
2nd filter analysis and help ensure transparency throughout the project. 
METHODS 
The research question 
The research question for the ACE–Obesity study was specified as: 
 
What are the best options towards which state and national resources should be directed to 
reduce unhealthy weight gain in children and adolescents in Australia? 
 
The reference year for all analyses was 2001, the latest year for which all key data sets were available. 
 
Study perspective 
Given the nature of obesity interventions and their likely settings in community-based facilities such as 
schools and child care facilities, a broad ‘societal perspective’ was adopted, but with a major focus on 
the health sector implications. All known costs and outcomes of the interventions were identified and 
then either included or excluded in the measurement stage, with reasons clearly specified (such as 
availability of data or likelihood of being impacted by the intervention). 
 
Choice of comparator 
One of the fundamental questions for economic evaluation is ‘what difference the option for change 
makes to current policy?’ Thus, the comparator to the interventions selected as options for change in 
the ACE studies was ‘current practice’ (refer Table 1). This recognises that resources currently being 
used could be integrated into a coordinated approach to the new intervention and/or that not all the 
benefits could automatically be attributed to the new intervention. This is often referred to as 
‘incremental analysis’, with the resulting cost-effectiveness ratios referred to as incremental cost-
effectiveness ratios (or ‘ICERs’). In ACE-Obesity we modelled current practice as a ‘no intervention’ 
comparator as very little activity, if anything, was currently happening. Even where there was some 
minor activity (e.g. in schools), there was considerable uncertainty as to what constituted ‘current 
practice’, what it cost, and how effective it was. The associated disease management cost and health 
impacts of this ‘no intervention’ comparator were modelled through time and became the potential cost 
offsets and potential health gains for the new interventions. 
 
Target population 
The actual Australian population of children and adolescents (aged 5-19 years) in the year 2001 was 
used and followed through time. The target groups within the Australian population for which the 
interventions were intended were clearly specified (refer Table 1). The relevant target group varied 
depending on the specific intervention; whether all persons in a particular age group, or a specific 
group of people (for example, all 8–11 year olds or overweight/obese 8–11 year olds).  

Time horizon 
The time horizon for providing an intervention reflected its real-life application, but with costs and 
outcomes reported for the cohort of children eligible for a particular intervention in the representative 
baseline year 2001. The time horizon for the tracking of the costs and benefits arising from an 
intervention was the remaining life span of the target cohort, i.e. until death or age 100 years. A 
cohort multi-state life table approach was developed for this purpose [8]. 
 
Regardless of the time horizon chosen, all interventions were assumed to be in ‘steady-state’ 
operation, meaning that they were working at their full effectiveness potential and that trained 
personnel and/or infrastructure were available, and set-up costs were excluded.  
 
Discounting 
Discounting at 3% per annum was applied to both costs and benefits. This rate approximates the long 
term bond rate, the rule of thumb often used in selecting the appropriate discount rate. It is also the 
rate recommended by a consensus panel of health economists in the USA for cost-effectiveness 
analysis [13].  
 
Selection of interventions 
The guiding economic principle of opportunity cost — that is, of benefit/benefit forgone in alternate 
uses of available funds — rests on the careful selection and specification of current practice and options 
for change. The selection of interventions for analysis was a difficult and time consuming task, given 
the limited evidence of effectiveness and requirement for clear specification [8]. After discussion, the 
Working Group agreed to the following selection criteria: 
 
1) relevance to current policy decision making; 
2) availability of evidence of efficacy/effectiveness to support meaningful analyses, using a broad 
definition of evidence;  
3) potential impact on addressing the problem of obesity; 
4) the ability to specify the intervention in clear concrete terms to facilitate meaningful evaluation; 
5) inclusion of a mix of interventions ranging from broad-based to narrower more specific 
interventions, and across a range of settings (community, schools, clinic, media); and 
6) considerations of program logic. 
 
The ACE-Obesity project had the resources over a two year period to evaluate the effectiveness and 
cost-effectiveness of 13 different obesity interventions in children and adolescents (Additional File 1). 
Priority was given to public health interventions that met ‘relevance to current policy decision making’ 
and ‘availability of evidence to support the analyses’. Discussion around reasons for exclusion of other 
interventions can be found in Haby et al [8].
Assessment of health benefits 
DALYs saved over the child’s lifetime was chosen as the measure of health gain. The methods for 
calculating the impact of the intervention on the Body Mass Index (BMI) post-intervention and then 
DALYs saved over the lifetime of the target population are described fully in Haby et al [8]. 
 
Assessment of costs 
A common convention in costing is to describe the analysis in three steps; identification, measurement 
and valuation [12]. 
 
Step One ~ Identification of costs 
For the identification step, the societal perspective adopted means that costs to both public health care 
providers (Commonwealth, State and Territory governments) and private sector (clients/participants, 
their family/carers) were included, as well as costs to sectors other than health (for example, 
education and infrastructure).   
 
The potential impacts of interventions on production in the general economy due to early return to 
work or reduced disease incidence (production losses/gains) were not included in ACE-Obesity, but are 
currently the basis of a separate study [14]. The inclusion of unrelated health care costs in additional 
years of life conferred by an intervention is a contentious issue amongst economists [12-13] and such 
costs were not included. While time costs for adults were included (e.g. parents and/or volunteers 
supporting an intervention), no allowance was made for the time costs of children and adolescents 
participating in an intervention. 
 
Step Two ~ Measurement of costs 
This step measures the quantities of resource used that stem from the intervention and its downstream 
effects.  
(i) Intervention costs 
Detailed pathway analysis was undertaken for each of the interventions. This entailed determining the 
probability of certain activities occurring and specifying the resources used in association with those 
activities. It was assumed that participants who did not adhere to the intervention incurred the 
intervention costs but received no benefit. One major issue of concern to accurate measurement was 
the attribution of costs to an intervention in situations where resources were jointly used by one or 
more programs.  For example, in interventions in the school setting, the costs of teachers, materials 
and equipment may be shared by several programs. The criteria used to distribute such joint costs 
were tabulated and varied under sensitivity analysis so that users of the study results can satisfy 
themselves that they were reasonable. 
 
(ii) Cost offsets 
Cost offsets are savings in future health sector expenditure that can be attributed to the reduction in 
BMI due to an intervention. Health sector expenditure for obesity-related diseases, calculated by the 
Australian Institute of Health and Welfare, was used [15]. These disease specific estimates are satellite 
estimates of the main health expenditure estimates and are based on a national accounts approach. 
They include expenditure on health goods and services, health-related services and health-related 
investment. They do not include: 
• expenditure that may have a ‘health’ outcome but which is undertaken outside the health sector, 
such as expenditure on building safer transport systems or the education of health professionals; 
• expenditure on personal activities not directly related to maintaining or improving personal 
health; 
• expenditure that does not have health as the main area of expected national benefit; or 
• time costs. 
It was assumed that the current (2001) average costs and clinical practice would be representative of 
future costs and practices.  
 
To determine the reduction in obesity-related costs for a particular intervention, we used the same 
methods as used for the calculation of DALYs saved [8]. In summary, we first converted the total 
current costs for each obesity-related disease for each sex and 10-year age group, to rates by dividing 
by 2001 Australian population figures and applying these to each of the two 5-year age groups within 
the 10-year age group. Disease-specific rates were summed to give total cost rates for obesity-related 
diseases for each sex and 5-year age group.  Total cost rates were extrapolated from 5-year to 1-year 
age groups for input into the base case life table using linear interpolation between data points. The 
change in the current and future BMI distribution of the target population due to the intervention was 
used to determine the potential impact fraction (PIF) for each 5-year age group and for males and 
females separately. The disease-specific cost rates for the intervention scenario were calculated as the 
base case cost rate x (1-PIF) for each age and sex category before input into the intervention life table.  
The difference between the base case and the intervention scenario gives the total obesity-related 
costs saved (cost-offsets).  This difference was applied to the total population benefiting from the 
intervention to get total cost-offsets.  
 
Step Three ~ Valuation of costs 
In the valuation step, a unit price for each of the activities, together with the data source, was 
specified. Costs were measured in real prices for the reference year (2001).  As interventions fell 
largely outside the health sector, adjustment was made using the relevant Consumer Price Index [16] 
rather than a health inflator. Intervention costs to the government health sector, clients/families, and 
non-health sectors were identified, measured and reported separately.  

Incremental cost effectiveness ratios (ICERs) 
The cost-effectiveness ratios were determined as the incremental cost of the intervention divided by 
the incremental benefit and presented as cost (AUD) per DALY saved (both with and without cost 
offsets). In related articles the full cost-effectiveness results for each intervention assessed are 
presented and analysed in detail. The ‘best options’ are defined as interventions which are cost-
effective as measured by the commonly used benchmark for cost-effectiveness in Australia of less than 
$50,000 per DALY (disability-adjusted life-year saved).
Uncertainty testing and sensitivity analysis 
Extensive ‘uncertainty testing’ was conducted to cover variation in those technical parameters (usually 
economic and epidemiological inputs) that have an impact on efficacy/effectiveness, unit costs, etc. 
’Sensitivity testing’, on the other hand, was defined to cover variation in key design features of an 
intervention, such as the delivery mode or the target age group and joint attribution of costs. 
 
Simulation-modelling techniques (with Monte Carlo sampling) using @Risk software [17] were used to 
allow the presentation of the 95% uncertainty range around the benefits, costs and cost-effectiveness 
ratios. This approach is recommended by the Canadian Coordinating Office for Health Technology 
Assessment [18] and the US Consensus Panel on Cost-Effectiveness in Health and Medicine [13]. The 
probability distributions around the input variables were based on standard errors or the range of 
parameter values quoted in, or calculated from, the literature; and/or from expert advice on the likely 
scenarios under Australian conditions. The @RISK analysis also showed the input parameters with the 
greatest influence on the final results and hence provided an indication of research priorities if greater 
accuracy of results was desired. 
 
The 2nd Stage Filter Criteria 
The 2nd stage filter analysis involved the assessment of issues that either influence the degree of 
confidence that can be placed in the cost-effectiveness ratios (such as the level of available evidence), 
or broader issues that need to be taken into account in decision-making about resource allocation. The 
filters used in the ACE-Obesity study were equity, strength of evidence, feasibility of implementation, 
acceptability to stakeholders, sustainability, and potential for side effects (Moodie et al 2009 as yet 
unpublished). 
 
RESULTS 
The costs for the 13 modelled interventions varied considerably, both in absolute terms and when 
expressed as a ‘cost per child’ estimate (refer Table 1). In terms of gross cost (i.e. ignoring potential 
cost offsets), costs for application Australia-wide, varied from AUD130m per annum (lap banding for 
severely obese adolescents), to less than AUD1m per annum (controlling TV advertising of ‘junk food’; 
targeted multi-faceted school-based program), raising affordability as an important issue for policy-
makers to consider. There were 3 interventions of high cost in Australian terms (i.e. >AUD40m per 
annum); 6 interventions of moderate cost (i.e. AUD10m-40m per annum; and 4 interventions of low 
cost (i.e. <AUD10m per annum).  
 
When potential cost offsets were included, however, the results changed considerably for some 
interventions. One high cost intervention moved to a net saving (multi-faceted school-based with 
physical activity); three moderate cost interventions moved to a net saving (education to reduce 
carbonated drinks in schools; family-based targeted program for obese children; education program to 
reduce TV viewing); and two low cost interventions moved to a net saving (regulation of TV 
advertising; targeted multi-faceted school-based program). For those moderate to high cost 
interventions where potential cost offsets were small, this was because anticipated health impacts were 
small (as health impacts and cost offsets are correlated), and the combination of moderate to high 
costs with small health gains, meant achieving cost-effectiveness (i.e. less than AUD50,000 per DALY) 
was likely to be a challenge.  
 
Expressing costs as a ‘net cost per child’ adds the important dimension of intervention reach and 
loading, to balance the simple focus on total costs. Some moderate to high cost interventions perform 
quite strongly on this indicator (Active After School Communities; TravelSmart; education to reduce TV 
viewing), as the setting and nature of the intervention mean that large numbers of children have 
access and/or capacity utilisation is stronger.  

Detailed cost effectiveness and 2nd stage filter results for each intervention will be published in 
upcoming papers. 
DISCUSSION 
The high variability in the cost results summarised in Table 1 raises affordability as a major policy 
consideration, in addition to concerns for effectiveness, efficiency and equity of access. In interpreting 
these cost results it is important to understand the impact of three key factors: first, the way in which 
the cost results are reported, which will suggest different take-home messages (i.e. ‘gross cost’, ‘net 
cost’ or ‘cost per child’); second, the impact of intervention-specific factors which clearly vary between 
interventions (refer ‘Key cost issues’ column of Table 1); and third, the impact of the evaluation 
protocol which is common to all the interventions evaluated and affects each in much the same way 
(refer last row of Table 1). 
   
Reporting costs as ‘gross costs’ (i.e. ignoring potential cost offsets) is important, because from a policy 
perspective, it closely approximates the financial budget that will be needed to operate the 
interventions. Reporting ‘net costs’ is important because cost offsets have a major influence on cost-
effectiveness, as well as the ongoing budget implications of funding interventions over the longer term. 
The role of cost offsets will focus decision-makers on their achievability, as well as foster a concern for 
who receives those cost offsets. Reporting costs as a ‘net cost per child’ adds the important dimension 
of intervention reach and loading, which is a useful process indicator, but should not be confused with 
the higher order efficiency of achieving outcomes. Some interventions with low ‘cost per child’ results, 
for example, may still be ineffective in achieving BMI reductions (e.g. TravelSmart), while some with 
high ‘cost per child’ results could be very effective in achieving health gains (e.g. Lap Banding). Thus 
high ‘costs per child’ results reflect factors like total cost, targeting and capacity utilisation, but are not 
necessarily synonymous with poor cost-effectiveness. 
 
Turning to the intervention-specific factors, it is clear that some interventions are over-burdened with 
extensive coordination and overhead costs, particularly when combined with poor utilisation of 
available capacity (e.g. Walking School Bus; Active After School Communities). As this situation applies 
to important current government initiatives at both the Commonwealth and State levels, we have 
undertaken careful examination of these cost structure and utilisation factors. The counterpoint to this 
observation is that some interventions have multiple objectives that include broader traffic congestion, 
community and environment goals (eg. TravelSmart, Walking School Bus). When a share of costs is 
attributed to these broader objectives, then cost performance is improved and/or affordability may be 
shared across a number of portfolios. Another important cost factor to consider is the potential to 
combine interventions or piggyback them on to existing programs (e.g. family-based GP program for 
moderately obese children). 
 
In terms of the cost protocol, key points to note are the inclusion of time costs for adults; the 
assumption of ‘steady-state’ costing; the annuitisation of capital items (equivalent to a lease); and the 
approach to cost offsets. The ‘steady-state’ assumption means that the technical analyses did not 
include a detailed ‘roll-out phase’ and did not address implementation or ‘learning curve’ issues. This 
reflects the priority setting context of the analyses, where multiple interventions are being assessed, 
and the research question is framed in terms of the potential cost-effectiveness of interventions if they 
are implemented in accordance with their effectiveness potential. This does not mean, however, that 
practical issues related to the feasibility and acceptability of implementation are ignored – rather, they 
are considered in the 2nd stage filter analysis. The ‘steady-state’ assumption keeps the technical 
analysis tractable and achieves comparability in the results across multiple interventions. 
 
There are several limitations in our approach to the calculation of cost offsets. Firstly, the cost offsets 
are based on the mean reduction in BMI continuing over the life of child (bias towards over-estimation) 
[19-20]. The reported cost-offset results are dependent on this maintenance of benefit assumption.  
We have acknowledged that there is a potential danger for this assumption to over-estimate the cost-
effectiveness results, but were constrained by the lack of evidence to the contrary in children. This will 
be addressed in individual papers where the sensitivity of results to this assumption will be explored. 
 
In addition, cost offsets use a health sector rather than a societal perspective (bias towards under-
estimation); time costs and other patient specific costs (eg travel costs) are not included in the health 
expenditure accounts; and not all health care expenditure could be allocated to specific diseases 
(around 13% involving ambulance assistance; aids and appliances; and aspects of community health), 
and as a result was not included (bias towards under-estimation). It is difficult to predict with any 
certainty the net effects of these biases.  
 
Turning to the broader issue of the ACE approach to priority setting, the strengths of the ACE–Obesity 
study include an evidence-based approach; the use of a common economic protocol to ensure 
comparability of the results; extensive uncertainty and sensitivity testing; interpretation of cost-
effectiveness ratios within a broader decision-making framework that includes consideration of second 
stage filter criteria; and the use of local data for demography, health system costs and offsets, disease 
incidence/prevalence, risk factors and disease burden. 
 
The main limitations of the ACE-Obesity study relate to evidence of effectiveness which was discussed 
in detail in Haby et al.[8] We use the Australian context to determine the health benefits, costs and 
incremental cost-effectiveness ratios. Therefore, care must be taken if trying to generalise the results 
to other countries. Some interventions may work differently in other countries due to differences in 
lifestyle, culture, beliefs and current practice in obesity prevention. The costs of implementing the 
interventions are also likely to vary between countries due to differences in salary structures, health 
systems, other unit costs and methods of implementation. The impact on total BMI units saved, DALYs 
averted and cost offsets will also vary according to differences in population size and structure and 
different disease rates between countries.  

CONCLUSIONS 
Despite the current limitations in evidence, the ACE–Obesity study provides useful information for 
policy-makers. To our knowledge there have been no similar attempts at determining affordability and 
effectiveness of interventions across a wide range of obesity interventions in a comparable manner. 
Despite considerable uncertainty around key input variables, clear distinctions in cost between obesity 
interventions were found, together with logical explanations for the differentials. Nevertheless, until 
there is greater evidence, including better evaluations of new and current interventions for preventing 
overweight and obesity, many of our estimates should be considered provisional, though strongly 
indicative of the relative magnitude of the health gain and costs. For some interventions, particularly 
those which are currently funded, our work indicates areas where cost performance could be carefully 
studied, with a view to improvements in cost structure and capacity utilisation. 
 
We hope the publication of individual intervention in future papers results will both encourage debate 
about future directions for health policy, and encourage further research to clarify those issues where 
current knowledge is lacking.   
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Table 1: Evaluation design frame for interventions chosen 
Interventions1,2 
and Setting 
Target 
Population3 
Cost Results  
Gross         Net Cost     Cost      
Cost      (Net Saving)   Child4 
                     Key cost issues 
1.  Active After 
School Communities 
Program [Child Care 
5]. Runs 8 weeks in 
each of the 4 school 
terms. 
Primary school 
children in Prep 
to Grade 6 (age 
5-11 years). 
Number ≈99 000  
$40.3m 
[UI: 
$28.6m-
$56.2m]6 
$36.5m 
[UI: 
$24.9m-
$52.6m] 
$407 
 
i) Extensive & “lumpy” salary costs, particularly  
for regional physical activity co-ordinators;  
ii) sub-optimal capacity utilisation; iii) cost data  
modelled, not empirically-based; and  
iv) BMI outcomes not commensurate with  
high cost structure. 
 
2.  Multi-faceted 
program, including 
education to 
improve nutrition & 
increase physical 
activity, without an 
active physical 
education 
component [School-
based]. 
 
Children in 
primary school 
Grades 1 and 2 
(commencing in 
Grade 1, age 6 
years). 
Number ≈114 630 
$24.3m 
[UI: 
$12.6m-
$39.2m] 
$9.0m 
[UI: net 
saving of 
$9.1m to 
net cost of 
$31.7m] 
$211 
 
i) Costs over 2 year-period taken as  
representative ‘annual cost’ as reflects  
concomitant cohorts; ii) included central &  
school coordination costs for national program,  
but not teacher time (as integrated into  
curriculum); iii) assumed uptake by schools  
does not vary by type of school (public or  
private); and iv) parent involvement  
encouraged as part of program but not costed. 
 
3.  Multi-faceted 
program, including 
education to 
improve nutrition & 
increase physical 
activity, with an 
active physical 
education 
component [School-
based]. 
Children in 
primary school 
Grades 1, 2 & 3 
(commencing 
Grade 1, age 6 
years). 
Number ≈114 630 
$54.2m 
[UI: 
$26.9m-
87.5m) 
($14.0m) 
[UI: net 
saving of 
$41.9m to 
net cost of 
$1.3m] 
$473 
 
i) Costs over 3 year-period taken as  
representative ‘annual cost’ as reflects  
concomitant cohorts; ii) included central &  
school coordination costs for national program, 
 but not teacher time (as integrated into  
curriculum); iii) physical activity component  
may pose problem for primary schools without  
specialist physical education teachers; iv)  
assumed uptake by schools does not vary by  
type of school; and v) parent involvement  
encouraged but not costed. 
 
4. Multi-faceted 
program [School-
based] targeted at 
overweight and 
obese children.  
 
Overweight or 
obese children 
aged 7-10 years 
(Grades 2-5) at 
combined 
primary/secondar
y school. 
Number ≈ 17 000 
over 4 years    (4 
200 each year) 
 
$2.2m 
[UI: 
$1.2m to 
$4.1m] 
($1.2m) 
[UI: net 
saving of 
$5.7m to 
net cost of 
$0.38m] 
$129  
  
 
i) Modelled as implemented over 4 yearsrather  
than implementing it to everyone eligible every  
4 years; ii) involves a peer-led program using  
8th grade students, supported by counsellors, to  
help obese children in grades 2-5; iii) counsellors 
costed as publicly funded psychologists employed 
on part-time basis (different to trial). 
 
5. Education 
program to reduce 
consumption of 
carbonated (fizzy) 
drinks[School-
based].   
Children in 
primary school 2 
to 6 (age 7-11 
years). 
Number ≈ 595 
000 implemented 
over 5 years 
(119,000 each 
year) 
 
$16.6m 
[UI: 
$7.6m -
$32.2m]  
($26.7m) 
[UI: net 
saving of 
$112.7m to 
net cost of 
$32.0m] 
 
$28 
  
i) Capacity calculated on seeing 1/5th of schools  
each year, not all schools every year; ii)  
assumes each child receives intervention once  
during primary school; and iii) assumption of no  
additional school staff costs as sessions  
presented by trained project staff. 
6.  Education 
program to reduce 
TV viewing [School-
based]. 
 
Children in 
primary school 
Grades 3 & 4 
(age 8-10 years). 
Number ≈268 600 
$27.7m 
[UI: 
$12.7m -
$43.3m] 
($43.8m) 
[UI: net 
saving of 
$81.8m to 
net saving 
of $6.6m] 
$103 
 
i) Modelling included national/state project  
officers to implement national program and full  
training costs for teachers, but not teacher time  
in the classroom (as integrated into curriculum);  
ii) 50% of schools participate in any one year;  
iii) assumed uptake by schools does not vary by  
type of school (public or private); and iv) parent  
involvement encouraged as part of program but  
not costed. 
 
7. TravelSmart 
Schools [Schools/ 
neighbourhoods & 
community 
organisations7] 
 
 
Children in 
primary school 
Grades 5 & 6 
(age 10-11 
years). 
Number ≈267 700 
$13.3m 
[UI: 
$6.9m -
$22.8m] 
 
$12.58m 
[UI: 
$6.1m- 
$222.1m] 
$50 
 
i) Large impact on cost-effectiveness from  
attributing a share of intervention costs to  
broader congestion, community & environmental  
objectives; ii) capacity utilisation not an issue for 
this intervention as 90% of costs are variable;  
and iii) cost data mostly modelled, not a strong  
empirical base. 
8. Walking School 
Bus [Schools/ 
neighbourhoods & 
community  
organisations]. 
Primary school 
children in Prep 
to Grade 2 (age 
5-7 years). 
Number ≈ 7 840 
$22.8m 
[UI: 
$16.6m-
$30.9m] 
$22.53m 
[UI: 
$16.35m- 
$30.47m] 
$290
8 
 
 
 
i) Extensive set-up & overhead costs; ii) poor  
capacity utilisation; iii) attribution of costs to  
non obesity objectives; iv) empirical data coming 
 from early developmental period of WSB  
program in Vic, Australia.   
 
9.  Reduction of TV 
advertising of high 
fat and/or high 
sugar foods & drinks 
to children [Media & 
marketing]. 
All Australian 
children aged 5-
14 years. 
Number ≈ 2.4 
million 
$0.13m 
[UI: 
$0.12m-
$0.14m] 
($299m) 
[UI: net 
saving of 
between 
$133m- 
$484m] 
$0.54 
 
Key issue is exclusion of costs other than cost  
of monitoring/ enforcing compliance with revised  
regulation. Excluded costs include: changing the  
regulations; any additional food costs to families  
in switch from non-core to core; impact on  
revenue stream of advertising companies &  
producers of non-core foods. 
 
10. Family-based GP 
program targeted at 
overweight and 
moderately obese 
children [Primary 
care services g] 
 
 
Overweight or 
moderately obese 
children aged 5-9 
years 
Number ≈ 9 685 
$6.3m 
[UI: 
$5.3m-
$7.4m] 
$2.95m 
[UI: net 
saving of 
$1.06m to 
net cost of 
$7.0m] 
$650 
 
i) Intervention design includes costs of family  
participation, but no additional benefits are  
included from weight loss to family members  
other than the child; ii) potential for  
piggy-backing this intervention into other  
GP-based interventions; iii) low % of fixed costs  
means cost drivers for affordability (patient  
numbers), do not impact much on  
cost-effectiveness; and iv) majority of cost  
incurred by government, but cost impact on  
family still significant, with time costs a major  
factor. 
 
11. Family-based 
targeted program 
for obese children 
[Primary care 
services9 + hospital 
setting delivery by 
multidisciplinary 
team]  
 
 
Obese children 
aged 10-11 
years. 
Number ≈ 5 800  
 
$11.0m 
[UI: 
$6.8m-
$18.3m] 
($4.0m) 
[UI: net 
saving of 
$19.0m to 
net cost of 
$2.4m] 
$1,89
6 
 
i) Recruitment component adjusted from  
screening in schools in RCT, to opportunistic  
recruitment via GPs; ii) assumed 50% of 6,000  
GPs already have calibrated scales and  
stadiometers necessary to measure weight; iii) 
 ‘intention to treat’ approach adopted for costing  
(i.e. non completion still involved intervention  
costs), but full completion of visits required  
before benefits attributed. 
 
12. Orlistat therapy 
for obese 
adolescents [Primary 
care services9]. 
 
 
Obese 
adolescents aged 
12-16 years.  
Number ≈ 3 256 
$6.3m 
[UI: 
$1.4m-
$20.0m] 
$4.9m 
[UI: 
$1.1m-
$15.9m] 
$1,93
5 
 
i) Modelling incorporated opportunistic  
recruitment in Australian primary care setting  
(by GPs with dieticians providing dietary advice)  
and conservative adherence rates (65%); ii) only 
patients responsive to Orlistat assumed to  
continue past 2-week run-in period; iii) costs to  
parents in accompanying adolescent included;  
iv) high proportion of costs falling on patients/ 
families (as Orlistat not on Pharmaceutical  
Benefits Schedule) impacts on access. 
  
13. Laparoscopic 
adjustable gastric 
banding (LAGB) for 
morbidly obese 
adolescents 
[Hospital10].  
 
 
Severely obese 
adolescents, aged 
14-19 years, with 
private health 
insurance 
Number ≈ 4 120 
 
$130m 
[UI: 
$52m-
$265m] 
$53.4m 
[UI: 
$20.1m-
$116.8m] 
$31,5
53 
 
i) Definition of ‘current practice’; ii) inclusion in  
costing of ongoing follow-up, including regular  
consultations and 2 LAGB replacements over  
lifetime; iii) cost data coming from early  
developmental period of LAGB (case series of  
28 patients) extrapolated to eligible adolescent  
population; and iv) management of  
co-morbidities assumed to be same for  
intervention and comparator. 
 
Protocol issues common to all interventions: i) Inclusion of time costs for adults/carers, but not children/adolescents; ii) 
exclusion of production gains/loses; iii) exclusion of unrelated costs in rest of life; iv) ‘steady-state’ costing,with program modeled 
in accordance with efficacy potential, assuming trained staff and infrastructure available; v) costs offsets based on mean 
reduction in BMI continuing over life of the child; vi) early set-up & development costs excluded (i.e. costs incurred before 
intervention commences, such as development of training packages); vii) annuitisation of capital, including human capital costs 
like training; and viii) full pathway costing, including recruitment and coordination. 
 
Notes:  
1 Current practice comparator defined as “no intervention” as programs either focussed on children previously inactive 
and/or minimal activity previously existed. 
2 The intervention period is defined as one representative year of “steady-state” operation, with “rest-of-life” modelling for 
all associated costs and benefits.  
3 Number of children participating in the intervention based on Australian population figures in 2001 and likely take-up rates. 
For some interventions, not all of the children/adolescents participating receive a health benefit from the intervention.  
4Cost per child estimates do not include cost offsets.  
5 Includes child care centres, family day care and outside school hours care.  
6  95% uncertainty interval 
7 Includes State/Territory government, local government, community groups, recreation and sporting bodies, and private 
organisations.  
8 Current regulations limit adverts to 5 minutes every 30 minutes during 5 hrs of designated child slots & prohibits 
advertisements during 2.5 hrs per week of designated pre-school timeslots.  
9 Includes general medical practice (GPs), community health centres and other community-based and private-sector 
services.   
10 The hospital setting was not included in ‘Healthy Weight 2008’ [21], but this clinical intervention was included in the 
project for purposes of comparison and benchmarking. 
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